Ann: onCARlytics to be showcased in three abstracts at SITC, page-81

I know a lot has been said about these abstracts. I jus thoughts I'd read through them and break down one of them (for my own benefit - and perhaps others)...Eureka + IMU...the below is taken from the abstracts...(except bolded titles).

Problem: HCC - second in the world!
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related deaths in the world

Current treatment: Liver transplant, removal of tumor but even so a 5-year survival rate at less than 12%.

Current problems with solid tumours...
a. Tumor express many different targets (antigens).
b. Micro- enviroment (TME) suppresses Immune system.

Oncarlytics + T cell Eureka...
a. Puts a target on tumor. (solves problem a - above)
b. OV - reshapes the TME. (solves problem b above).

Conclusion...
"In summary, ARTEMIS® CD19 T cells combined with onCARlytics is a potentially effective immunotherapy strategy for the treatment of patients with HCC and can be applied to other solid tumors"

I know this is a. only pre-clinical and b. is there interest with BP? However the magnitude of this is just staggering, even if it only comes off at 20% of the potential.

DYOR and all that.